DRUG FOR INFLAMMATORY BOWEL DISEASE
Anti-CD81 antibody displays not only a remission induction effect, but also a long-term remission maintenance effect on inflammatory bowel disease when administered in a single dose, and is therefore effective as a drug for maintaining remission from inflammatory bowel disease. Moreover, anti-CD81 antibody is effective as a drug for the prevention, amelioration and treatment of inflammatory bowel disease because it has preventive, therapeutic and ameliorating effects on refractory inflammatory bowel disease.
1 . A method for maintaining remission of inflammatory bowel disease, comprising administering an anti-CD81 antibody to a subject in need thereof.
2 . A method for preventing, ameliorating, or treating refractory inflammatory bowel disease, comprising administering an anti-CD81 antibody to a subject in need thereof.
3 . The method according to claim 2 , wherein the refractory inflammatory bowel disease refers to inflammatory bowel disease with repeated relapse or recurrence or inflammatory bowel disease with chronically persistent disease activity.
4 . The method according to claim 2 , wherein the refractory inflammatory bowel disease is a steroid-dependent or steroid-resistant inflammatory disease.
5 . The method according to claim 2 , wherein the refractory inflammatory bowel disease refers to inflammatory bowel disease that is resistant or tolerant to usual treatment.
6 . The method according to claim 5 , wherein the usual treatment refers to administration of an existing therapeutic drug.
7 . The method according to claim 6 , wherein the existing therapeutic drug is a 5-aminosalicylic acid preparation, steroid, an immunosuppressant, a TNF inhibitor, or an integrin inhibitor.
8 . The method according to claim 7 , wherein the existing therapeutic drug is sulfasalazine, an anti-TNF antibody, salazosulfapyridine, mesalazine, betamethasone, betamethasone sodium phosphate, betamethasone phosphate, prednisolone, azathioprine, tacrolimus, 6-mercaptopurine, cyclosporine, infliximab, adalimumab, certolizumab, pegol, or natalizumab.
9 . The method according to claim 1 , wherein a long-term remission-maintaining effect is exerted by single-dose administration.
10 . The method according to claim 9 , wherein the remission-maintaining effect is an effect of maintaining a state of remission by inhibiting repetition of relapse or recurrence of intestinal inflammation.
11 . The method according to claim 1 , wherein an anti-CD81 antibody is administered to a patient with inflammatory bowel disease in whom remission cannot be maintained by single-dose administration or even by multiple-dose administration of an existing therapeutic drug.
12 . The method according to claim 11 , wherein the existing drug is 5-aminosalicylic acid preparation, steroid, an immunosuppressant, a TNF inhibitor, an integrin inhibitor, sulfasalazine, an anti-TNF antibody, salazosulfapyridine, mesalazine, betamethasone, betamethasone sodium phosphate, betamethasone phosphate, prednisolone, azathioprine, tacrolimus, 6-mercaptopurine, cyclosporine, infliximab, adalimumab, certolizumab, pegol, or natalizumab.
13 . The method according to claim 1 , wherein the anti-CD81 antibody is administered once every 2 to 30 weeks during a period of treatment.
14 . The method according to claim 13 , wherein a dose per administration is 0.01 to 15 mg/kg.
15 . The method according to claim 1 , wherein the inflammatory bowel disease is ulcerative colitis.
16 . The method according to claim 1 , wherein the inflammatory bowel disease is Crohn's disease.